Accuracy of PREDICT+ to Determine OS in Early Breast Cancer
Elisa Agostinetto, MD, discusses the accuracy of PREDICT+, an online tool used to predict mortality in patients with early breast cancer patients and to aid in clinical decision making, to determine the survival of patients enrolled in the phase 3 ALTTO trial of adjuvant lapatinib with or without trastuzumab versus trastuzumab alone in patients with HER2+ early breast cancer.
Elisa Agostinetto, MD of the Istituto Clinico Humanitas, Rozzano, Milan, Italy, discusses the accuracy of PREDICT+, an online tool used to predict mortality in patients with early breast cancer patients and to aid in clinical decision making, to determine the survival of patients enrolled in the phase 3 ALTTO trial (NCT00490139) of adjuvant lapatinib (Tykerb) with or without trastuzumab (Herceptin) versus trastuzumab alone in patients with HER2+ early breast cancer.
According to Agostinetto, PREDICT+ underestimated the survival of patients in the ALTTO trial. The 5-year overall survival (OS) prediction was 6.7 percentage points lower than what the actual 5-year OS was. These findings were consistent across all subgroups.
The greatest discrepancies were seen in patients with hormone receptor negative disease, node positive disease, and patients with larger tumor sizes. Discriminatory accuracy was also found to be low in the overall population. This finding was consistent across all subgroups.
FDA Grants Clearance for Phase 1 Trial of BL-M17D1 in Solid Tumors
November 11th 2024Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel antibody-drug conjugate BL-M17D1 in patients with advanced or metastatic solid tumors.
Read More
T-DXd Use in HER2+ Breast Cancer Influenced by Site of Metastases and AE Monitoring
October 21st 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article of a 2-part series.
Read More
Wei Assesses Role of TROP2 and HER2 Status in Treatment With Sacituzumab for ER+ mBC
September 26th 2024During an in-person Community Case Forum in partnership with the Rocky Mountain Oncology Society, Mei Wei, MD, discussed data from the TROPiCS-02 trial of sacituzumab govitecan in patients with metastatic breast cancer.
Read More
